Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Burkitt Lymphoma 13Leukemia, Biphenotypic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Down Syndrome 3Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Leukemia 2Sarcoma, Myeloid 1Recurrence 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphohistiocytosis, Hemophagocytic 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 11Dexamethasone 10Cytarabine 10Vincristine 8Methotrexate 7merphos 5Mercaptopurine 5Doxorubicin 5venetoclax 4pegaspargase 4dexamethasone acetate 4dexamethasone 21-phosphate 4blinatumomab 4azathiopurine 4auricularum 4Specimen Handling 4Prednisone 4Leucovorin 4Inotuzumab Ozogamicin 4Calcium Dobesilate 4prednylidene 3deltacortene 3Thioguanine 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3Asparaginase 3calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2Spinal Puncture 2Rituximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Asparaginase × 1 year × Clear all
NCT02981628 2026-06-05

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡